SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with ...

Fintel reports that on January 7, 2025, B of A Securities upgraded their outlook for Erasca (NasdaqGS:ERAS) from Neutral to ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

including MAPK signaling pathway and ERK1/ERK2 cascade (Figures 4B, C), which regulate cell proliferation, differentiation, and migration. Cell proliferation and differentiation are well controlled in ...

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...

BAY3498264, when combined with a KRAS targeting agent, could slow or inhibit cancer cell growth by enhancing the effectiveness of KRAS inhibition. This dual approach aims to improve treatment ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...